The Novo Nordisk (NYSE:NVO) Foundation, which has the controlling holding of Novo Nordisk (NYSE:NVO), has announced an investment of around $265 million to establish a new initiative focused on enhancing vaccines for respiratory diseases.
This move comes as the foundation's financial resources have significantly increased due to the success of Novo Nordisk (NYSE:NVO)'s weight-loss drug, Wegovy.
The initiative, in collaboration with the University of Copenhagen, aims to develop new or improved vaccines for deadly respiratory illnesses such as tuberculosis, influenza, and group A streptococcus.
These diseases are responsible for over 2.5 million deaths annually. The foundation's project is unique as it concentrates solely on understanding how to generate immunity in the airway.